ResProly

瑞思普利

ResProly

Biotech/Healthcare

Founded in 2018, Resipoly develops and manufactures advanced inhaled drug formulations and delivery devices for respiratory diseases. Its pipeline covers a broad range of respiratory products targeting high-need therapeutic areas, including asthma, chronic obstructive pulmonary disease (COPD), and…

Latest round: Post-IPO (2025)

Source: ChinaBulls — chinabulls.com

Last updated 2025-06-01